Rituximab for treatment of inhibitors in haemophilia a: A phase II study

Cindy Leissinger, Cassandra D. Josephson, Suzanne Granger, Barbara A. Konkle, Rebecca Kruse-Jarres, Margaret V. Ragni, Janna M. Journeycake, Leonard Valentino, Nigel S. Key, Joan C. Gill, Keith R. McCrae, Ellis J. Neufeld, Catherine Manno, Leslie Raffini, Kapil Saxena, Marcela Torres, Victor Marder, Carolyn M. Bennett, Susan F. Assmann

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The development of antibodies against infused factor VIII (FVIII) in patients with haemophilia A is a serious complication leading to poorly controlled bleeding and increased morbidity. No treatment has been proven to reduce high titre antibodies in patients who fail immune tolerance induction or are not candidates for it. The Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (RICH) study was a phase II trial to assess whether rituximab can reduce anamnestic FVIII antibody (inhibitor) titres. Male subjects with severe congenital haemophilia A and an inhibitor titre ≥5 Bethesda Units/ml (BU) following a FVIII challenge infusion received rituximab 375 mg/m² weekly for weeks 1 through 4. Post-rituximab inhibitor titres were measured monthly from week 6 through week 22 to assess treatment response. Of 16 subjects who received at least one dose of rituximab, three (18.8%) met the criteria for a major response, defined as a fall in inhibitor titre to <5 BU, persisting after FVIII re-challenge. One subject had a minor response, defined as a fall in inhibitor titre to <5 BU, increasing to 5–10 BU after FVIII re-challenge, but <50% of the original peak inhibitor titre. Rituximab is useful in lowering inhibitor levels in patients, but its effect as a solo treatment strategy is modest. Future studies are indicated to determine the role of rituximab as an adjunctive therapy in immune tolerisation strategies.

Original languageEnglish (US)
Pages (from-to)445-458
Number of pages14
JournalThrombosis and Haemostasis
Volume112
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Hemophilia A
Factor VIII
Therapeutics
Antibodies
Immune Tolerance
Rituximab
Hemorrhage
Morbidity

Keywords

  • Anti-CD20
  • Antibodies
  • Blood coagulation inhibitor
  • CD20 antibody
  • Haemophilia A
  • Monoclonal
  • Murine-derived

ASJC Scopus subject areas

  • Hematology

Cite this

Leissinger, C., Josephson, C. D., Granger, S., Konkle, B. A., Kruse-Jarres, R., Ragni, M. V., ... Assmann, S. F. (2014). Rituximab for treatment of inhibitors in haemophilia a: A phase II study. Thrombosis and Haemostasis, 112(3), 445-458. https://doi.org/10.1160/TH14-01-0078

Rituximab for treatment of inhibitors in haemophilia a : A phase II study. / Leissinger, Cindy; Josephson, Cassandra D.; Granger, Suzanne; Konkle, Barbara A.; Kruse-Jarres, Rebecca; Ragni, Margaret V.; Journeycake, Janna M.; Valentino, Leonard; Key, Nigel S.; Gill, Joan C.; McCrae, Keith R.; Neufeld, Ellis J.; Manno, Catherine; Raffini, Leslie; Saxena, Kapil; Torres, Marcela; Marder, Victor; Bennett, Carolyn M.; Assmann, Susan F.

In: Thrombosis and Haemostasis, Vol. 112, No. 3, 2014, p. 445-458.

Research output: Contribution to journalArticle

Leissinger, C, Josephson, CD, Granger, S, Konkle, BA, Kruse-Jarres, R, Ragni, MV, Journeycake, JM, Valentino, L, Key, NS, Gill, JC, McCrae, KR, Neufeld, EJ, Manno, C, Raffini, L, Saxena, K, Torres, M, Marder, V, Bennett, CM & Assmann, SF 2014, 'Rituximab for treatment of inhibitors in haemophilia a: A phase II study', Thrombosis and Haemostasis, vol. 112, no. 3, pp. 445-458. https://doi.org/10.1160/TH14-01-0078
Leissinger C, Josephson CD, Granger S, Konkle BA, Kruse-Jarres R, Ragni MV et al. Rituximab for treatment of inhibitors in haemophilia a: A phase II study. Thrombosis and Haemostasis. 2014;112(3):445-458. https://doi.org/10.1160/TH14-01-0078
Leissinger, Cindy ; Josephson, Cassandra D. ; Granger, Suzanne ; Konkle, Barbara A. ; Kruse-Jarres, Rebecca ; Ragni, Margaret V. ; Journeycake, Janna M. ; Valentino, Leonard ; Key, Nigel S. ; Gill, Joan C. ; McCrae, Keith R. ; Neufeld, Ellis J. ; Manno, Catherine ; Raffini, Leslie ; Saxena, Kapil ; Torres, Marcela ; Marder, Victor ; Bennett, Carolyn M. ; Assmann, Susan F. / Rituximab for treatment of inhibitors in haemophilia a : A phase II study. In: Thrombosis and Haemostasis. 2014 ; Vol. 112, No. 3. pp. 445-458.
@article{719dd371af88441db77d597739920e38,
title = "Rituximab for treatment of inhibitors in haemophilia a: A phase II study",
abstract = "The development of antibodies against infused factor VIII (FVIII) in patients with haemophilia A is a serious complication leading to poorly controlled bleeding and increased morbidity. No treatment has been proven to reduce high titre antibodies in patients who fail immune tolerance induction or are not candidates for it. The Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (RICH) study was a phase II trial to assess whether rituximab can reduce anamnestic FVIII antibody (inhibitor) titres. Male subjects with severe congenital haemophilia A and an inhibitor titre ≥5 Bethesda Units/ml (BU) following a FVIII challenge infusion received rituximab 375 mg/m² weekly for weeks 1 through 4. Post-rituximab inhibitor titres were measured monthly from week 6 through week 22 to assess treatment response. Of 16 subjects who received at least one dose of rituximab, three (18.8{\%}) met the criteria for a major response, defined as a fall in inhibitor titre to <5 BU, persisting after FVIII re-challenge. One subject had a minor response, defined as a fall in inhibitor titre to <5 BU, increasing to 5–10 BU after FVIII re-challenge, but <50{\%} of the original peak inhibitor titre. Rituximab is useful in lowering inhibitor levels in patients, but its effect as a solo treatment strategy is modest. Future studies are indicated to determine the role of rituximab as an adjunctive therapy in immune tolerisation strategies.",
keywords = "Anti-CD20, Antibodies, Blood coagulation inhibitor, CD20 antibody, Haemophilia A, Monoclonal, Murine-derived",
author = "Cindy Leissinger and Josephson, {Cassandra D.} and Suzanne Granger and Konkle, {Barbara A.} and Rebecca Kruse-Jarres and Ragni, {Margaret V.} and Journeycake, {Janna M.} and Leonard Valentino and Key, {Nigel S.} and Gill, {Joan C.} and McCrae, {Keith R.} and Neufeld, {Ellis J.} and Catherine Manno and Leslie Raffini and Kapil Saxena and Marcela Torres and Victor Marder and Bennett, {Carolyn M.} and Assmann, {Susan F.}",
year = "2014",
doi = "10.1160/TH14-01-0078",
language = "English (US)",
volume = "112",
pages = "445--458",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "3",

}

TY - JOUR

T1 - Rituximab for treatment of inhibitors in haemophilia a

T2 - A phase II study

AU - Leissinger, Cindy

AU - Josephson, Cassandra D.

AU - Granger, Suzanne

AU - Konkle, Barbara A.

AU - Kruse-Jarres, Rebecca

AU - Ragni, Margaret V.

AU - Journeycake, Janna M.

AU - Valentino, Leonard

AU - Key, Nigel S.

AU - Gill, Joan C.

AU - McCrae, Keith R.

AU - Neufeld, Ellis J.

AU - Manno, Catherine

AU - Raffini, Leslie

AU - Saxena, Kapil

AU - Torres, Marcela

AU - Marder, Victor

AU - Bennett, Carolyn M.

AU - Assmann, Susan F.

PY - 2014

Y1 - 2014

N2 - The development of antibodies against infused factor VIII (FVIII) in patients with haemophilia A is a serious complication leading to poorly controlled bleeding and increased morbidity. No treatment has been proven to reduce high titre antibodies in patients who fail immune tolerance induction or are not candidates for it. The Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (RICH) study was a phase II trial to assess whether rituximab can reduce anamnestic FVIII antibody (inhibitor) titres. Male subjects with severe congenital haemophilia A and an inhibitor titre ≥5 Bethesda Units/ml (BU) following a FVIII challenge infusion received rituximab 375 mg/m² weekly for weeks 1 through 4. Post-rituximab inhibitor titres were measured monthly from week 6 through week 22 to assess treatment response. Of 16 subjects who received at least one dose of rituximab, three (18.8%) met the criteria for a major response, defined as a fall in inhibitor titre to <5 BU, persisting after FVIII re-challenge. One subject had a minor response, defined as a fall in inhibitor titre to <5 BU, increasing to 5–10 BU after FVIII re-challenge, but <50% of the original peak inhibitor titre. Rituximab is useful in lowering inhibitor levels in patients, but its effect as a solo treatment strategy is modest. Future studies are indicated to determine the role of rituximab as an adjunctive therapy in immune tolerisation strategies.

AB - The development of antibodies against infused factor VIII (FVIII) in patients with haemophilia A is a serious complication leading to poorly controlled bleeding and increased morbidity. No treatment has been proven to reduce high titre antibodies in patients who fail immune tolerance induction or are not candidates for it. The Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (RICH) study was a phase II trial to assess whether rituximab can reduce anamnestic FVIII antibody (inhibitor) titres. Male subjects with severe congenital haemophilia A and an inhibitor titre ≥5 Bethesda Units/ml (BU) following a FVIII challenge infusion received rituximab 375 mg/m² weekly for weeks 1 through 4. Post-rituximab inhibitor titres were measured monthly from week 6 through week 22 to assess treatment response. Of 16 subjects who received at least one dose of rituximab, three (18.8%) met the criteria for a major response, defined as a fall in inhibitor titre to <5 BU, persisting after FVIII re-challenge. One subject had a minor response, defined as a fall in inhibitor titre to <5 BU, increasing to 5–10 BU after FVIII re-challenge, but <50% of the original peak inhibitor titre. Rituximab is useful in lowering inhibitor levels in patients, but its effect as a solo treatment strategy is modest. Future studies are indicated to determine the role of rituximab as an adjunctive therapy in immune tolerisation strategies.

KW - Anti-CD20

KW - Antibodies

KW - Blood coagulation inhibitor

KW - CD20 antibody

KW - Haemophilia A

KW - Monoclonal

KW - Murine-derived

UR - http://www.scopus.com/inward/record.url?scp=84907270053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907270053&partnerID=8YFLogxK

U2 - 10.1160/TH14-01-0078

DO - 10.1160/TH14-01-0078

M3 - Article

C2 - 24919980

AN - SCOPUS:84907270053

VL - 112

SP - 445

EP - 458

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 3

ER -